The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.50
Bid: 9.30
Ask: 9.50
Change: -0.35 (-3.59%)
Spread: 0.20 (2.151%)
Open: 9.55
High: 10.00
Low: 9.50
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues outlook on Jersey Electricity (JEL)

14 Mar 2019 12:39

Edison Investment Research Limited Edison issues outlook on Jersey Electricity (JEL) 14-March-2019 / 12:38 GMT/BST


London, UK, 14 March 2019

Edison issues outlook on Jersey Electricity (JEL)

Jersey Electricity's (JEL) strong financial position and forecast cash flow should underpin 5% per year growth in the dividend per share. Although JEL faces wholesale cost rises, lower unit demand and a fluid regulatory situation, we believe that, given its strong position on pricing and service standards, it is well positioned to withstand these pressures. Our latest valuation analysis indicates increased upside potential from current levels.

Our updated valuation (the average of peer group multiples, using cover-adjusted yield/DCF/SOTP), indicates a valuation of c 560p (+2.5%) versus 546p last year. In particular, the increased SOTP valuation (from 552p to 592p) has been driven by a growth in regulatory assets and reduced debt. Despite a recent rise in the share price following the better than expected FY18 results released in December 2018, the shares offer 20% upside to the average of our valuation, with the prospect of growing income from the dividend.Click here to view the full report.

All reports published by Edison are available to download free of charge from its websitewww.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Graeme Moyse, +44 (0)20 3077 5700industrials@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_ResYouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

787643 14-March-2019 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
21st Jun 201612:59 pmRNSIssue of Equity
7th Jun 20162:08 pmRNSIssue of Equity and Directors' shareholdings
1st Jun 20167:00 amRNSSearchbolt Offer becomes wholly unconditional
27th May 20163:18 pmRNSResult of General Meeting
25th May 20162:59 pmRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
13th May 20164:08 pmRNSNotice of General Meeting - Correction
12th May 201610:50 amRNSDirector/PDMR Shareholding
11th May 20167:00 amRNSProposed Acquisition of Searchbolt, Notice of GM
15th Apr 201612:19 pmRNSNotice of AGM and Annual Report
22nd Mar 20167:00 amRNSFinal Results
4th Mar 20167:00 amRNSNotice of Results
15th Feb 20167:00 amRNSTop-line Phase IIb results update
6th Jan 20167:00 amRNSAppointment of Non-Executive Chairman
15th Dec 20153:38 pmRNSHolding(s) in Company
30th Nov 20154:48 pmRNSHolding(s) in Company
29th Oct 20157:00 amRNSAppointment of Non-Executive Director
29th Sep 20157:00 amRNSHalf Yearly Report
17th Sep 20157:05 amRNSNotice of Half Year Results
17th Sep 20157:00 amRNSChange of Nominated Adviser and Broker
10th Sep 20159:00 amRNSDirector's Disclosure
17th Aug 20157:00 amRNSHalf year trading and commercial strategy update
19th Jun 20158:38 amRNSExercise of Options
11th Jun 201511:31 amRNSResult of AGM
11th Jun 20157:00 amRNSAGM Statement
21st May 20157:00 amRNSProgress in ETS2101 Phase Ib Study
7th May 20157:00 amRNSNotice of AGM and Annual Report
31st Mar 20157:00 amRNSFinal Results
11th Mar 20154:08 pmRNSHolding(s) in Company
11th Mar 201512:41 pmRNSHolding(s) in Company
10th Mar 20157:03 amRNSNotice of Full Year Results
6th Mar 20152:22 pmRNSHolding(s) in Company
26th Feb 20151:55 pmRNSStmnt re Share Price Movement
21st Jan 201511:20 amRNSDirector/PDMR Shareholding
7th Jan 20157:00 amRNSAwards made under Performance Share Plan
7th Jan 20157:00 amRNSIssue of Equity
5th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSe-Therapeutics' Impact is rated World Class
18th Dec 20147:00 amRNSUpdate: ETS2101 Phase 1a and Oral Dosing Studies
27th Nov 20147:00 amRNSResearch and Development presentation to Investors
16th Oct 20148:35 amRNSAppointment of Executive Director
16th Sep 20147:00 amRNSHalf Yearly Report
4th Sep 20142:55 pmRNSNotice of Results
5th Aug 20147:00 amRNSAdditional Listing
1st Aug 20149:22 amRNSIssue of equity and Directors' shareholdings
9th Jul 201411:31 amRNSAGM Statement
9th Jul 20147:00 amRNSAwards made under Performance Share Plan
4th Jul 20147:00 amRNSDirector/PDMR Shareholding
27th Jun 20147:00 amRNSChange of Adviser
25th Jun 20144:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.